Intra Cellular Therapies reported $759.76M in Current Assets for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Acadia Pharmaceuticals ACAD:US USD 521.55M 10.97M
ALKERMES ALKS:US USD 1.05B 7.81M
Aptinyx Inc APTX:US USD 73.95M 18.19M
Biogen BIIB:US USD 9.77B 24.9M
Bristol Myers Squibb BMY:US USD 26.8B 3.39B
Cytokinetics CYTK:US USD 884.28M 282.02M
Esperion Therapeutics ESPR:US USD 261.78M 9.31M
Gilead Sciences GILD:US USD 13.9B 723M
Halozyme Therapeutics HALO:US USD 653.2M 111.26M
Intra Cellular Therapies ITCI:US USD 759.76M 29.45M
JAZZ PHA JAZZ:US USD 2.57B 19.33M
Marinus Pharmaceuticals MRNS:US USD 177.01M 75.91M
Minerva Neurosciences NERV:US USD 44.84M 5.2M
Nektar Therapeutics NKTR:US USD 599.48M 66.05M
Neurocrine Biosciences NBIX:US USD 1.21B 186.2M
Novartis NVS:US USD 36.95B 1.19B
Prothena PRTA:US USD 524.56M 3.27M
Supernus Pharmaceuticals SUPN:US USD 663.89M 38.77M
United Therapeutics UTHR:US USD 3.06B 372.1M
Vanda Pharmaceuticals VNDA:US USD 507.11M 10.21M